Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT

NCT05623267 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

346

Enrollment

OTHER

Sponsor class

Conditions

Limited Stage Small Cell Lung Cancer

Interventions

DRUG: Sugemalimab
DRUG: Placebo

Sponsor

Sun Yat-sen University